Compare Logitech International SA (LOGI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Mesoblast Limited — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Logitech International SA is far larger — about 8.3× Mesoblast Limited's market cap, and Logitech International SA pays a 1.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Mesoblast Limited for 15 Days on average.
| LOGI | MESO | |
|---|---|---|
Market Cap | $14.46B | $1.75B |
Volume | 349,547 | 239,027 |
Sector | Technology | Health |
52-Week High | $126.69 | $20.96 |
52-Week Low | $85.84 | $13.19 |
Typical Hold Time | 92 Days | 15 Days |
Enterprise Value | $12.79B | $1.83B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with a neutral technical signal and key support at $100. The company demonstrates strong fundamentals with a 16.28% net income margin and consistent earnings beats in recent quarters. Recent product launches like the Zone Vibe Pro headset and partnership with SEGA for Crazy Taxi: World Tour highlight ongoing innovation. Cash flow trends show robust operational performance, with 2025 operating cash flow of $842.56 million.
The outlook is cautiously optimistic, supported by a consensus price target of $107.00 implying modest upside. Investment opportunities include sustained profitability and strategic growth initiatives, while risks involve competitive pressures and potential supply chain disruptions as noted in recent CEO commentary. Analyst sentiment is mixed with a Hold-heavy consensus, reflecting balanced near-term expectations.
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
